




Chemistry & Biology March 1998, 
5:R63-R64 
0 Current Biology Ltd ISSN 1074-5521 
There is a bold sociological 
experiment being planned in South 
San Francisco, but its execution will 
have to wait on the fate of a single 
compound. Shaman Pharmaceuticals, 
Inc., is basing their development of 
natural product drugs on the 
knowledge of native healers. 
ProvirTM, a diarrhea treatment 
derived from the red latex of a plant 
with the familiar name sangre de 
drago (dragon’s blood), is their shot at 
the big time. If it succeeds, the real 
experiment begins: distribution of a 
percentage of the profits to 
collaborators in 70 different language 
groups in 30 different countries. 
New drugs from an old source 
The idea behind Shaman is simple. 
“We want to utilize this information 
base that native people have, to 
recognize that they have had a long 
history of using these plants,” says 
Wayne Inman, associate director of 
natural products chemistry at Shaman. 
Looking for drugs in plants is far from 
new: an estimated 120 drugs based on 
plant products are now on the market. 
Some of the more famous examples 
include quinine for malaria (from the 
bark of Peruvian cinchona trees), 
salicin (from white willow bark, 
converted to aspirin by Bayer in 
1899), and opiates (from the opium 
poppy). But Shaman is the first 
company to devote itself to finding 
these chemicals by systematically 
consulting native peoples, using 
ethnobotanist-physician teams. 
David Kingston of Virginia 
Polytechnic Institute and State 
University in Blacksburg, Virginia, is 
trying to find out whether native 
healers are worth the effort. As group 
leader of one of five LJS-government- 
sponsored International Cooperative 
Biodiversity Groups (ICBGs), he is 
coming to a mixed conclusion. 
“Probably for high throughput 
screening, a random botanical 
collection is just as good [as consulting 
native healers],” he says. “The 
particular screen has no relation to the 
shaman’s information, so you wouldn’t 
expect a correlation.” These in ah-o 
screens, typically performed in large 
numbers against proteins known to 
cause disease, are the favored tools of 
large pharmaceutical companies. But 
Shaman takes a very different 
approach, testing only a few, hand- 
picked plant extracts (-100 per year) 
in animal models of the disease. 
“Then I would expect to find quite a 
high correlation between the shaman’s 
information and an increased hit rate.” 
says Kingston, “because you are 
testing for something that is relevant 
to the disease indication.” 
With native people acting as a 
first-line screen for activity and 
bioavailability, Shaman scientists 
report that -SO% of their extracts 
show activity in initial in aho tests. 
But the animal models are not 
perfect. The researchers track a 
variety of physiological markers, but 
they do not know the exact 
mechanism of action of the extract, so 
rational modification of the isolated 
compound is difficult. And the target 
may be involved in the symptoms not 
the cause of the disease, although the 
success of drugs like aspirin makes 
this caveat seem less than troubling. 
Dragon’s blood 
The polyphenol from Croton lec/lleti, 
now called Provir, was initially 
identified as a potential treatment for 
respiratory synctial virus. It became an 
anti-diarrhea candidate when Shaman 
scientists witnessed use of Croton 
I&leti during a cholera outbreak in 
Peru in 1993. The switch in 
indications appears to have been a 
good decision. FVhen separated from 
other compounds in the plant extract, 
the polyphenol has poor 
bioavailability. This is a plus for 
diarrhea treatment, as the compound 
can be administered orally and reach 
high concentrations in the gut without 
showing toxicity. It appears to act, at 
least in part, by blocking the excretion 
of chloride ions by the cystic fibrosis 
transmembrane conductance regulator 
(CFTR), a channel found in both the 
lungs and the gut. By reducing ion 
secretion, Provir slows the loss of 
water in secretory diarrhea and allows 
the body to rid itself of toxins and 
bacteria at a more gradual pace. 
Shaman is marketing Provir as an 
alternative to antibiotics, which 
require diagnosis of the causative 
organism, and antimotility agents, 
which often result in rebound 
diarrhea once treatment is stopped. 
Phase II trials of Provir for mild 
diarrhea were not successful, but 
Shaman is pursuing Phase II trials for 
more serious traveler’s diarrhea, and a 
single pivotal phase III trial for AIDS- 
related diarrhea starts hlarch 1998. 
Shaman ’s next move 
Many biotech start-ups are glorified 
branch divisions of large 
pharmaceutical companies, with most 
of the research funds coming from, 
and most of the potential profits going 
to the partner. This is not the case for 
Shaman. After almost nine years and 
$104.5 million in accumulated 
deficits, Shaman is still blazing the 
trail with Provir. If it makes it to the 
finish line the rewards will keep the 
company going for a long time. 
Shaman was also on its own with 
\‘irendTM, a topical formulation of the 
polyphenol found in Provir. This 
drug died in Phase III trials for 
herpes. But in diabetes and anti- 
fungals the company is increasing the 
level of collaboration. An anti-fungal 
called Nikkomycin 2, licensed from 
Bayer after they discovered it would 
not work for the huge market of 
candidiasis, is now in Phase I trials for 
various fungal infections, including 
some that are particularly 
troublesome in AIDS patients. 
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Shaman’s discovery efforts are 
now focussed solely on therapies for 
non-insulin-dependent (adult-onset) 
diabetes (NIDDM). This disease is a 
good fit for the in viva approach. 
Current drugs, such as the 
sulfonylureas and metformin, have 
significant drawbacks, and further 
discovery using in vitro assays is 
hampered by the multiple causes of 
the disease. 
NIDDM is not a new disease; it 
was described in China as early as 
3000 B.C. But it does not dominate 
the thoughts of the developing 
world. Fortunately, its symptoms 
lend themselves to simple cross- 
cultural translation. The obvious 
symptoms - fatigue, chronic foot 
sores, and increased urination and 
thirst-can be supplemented with 
the less obvious: urine that attracts 
ants and leaves a white, sugary spot 
when dry. “In many cultures of the 
world,” explains Tom Carlson, senior 
director of ethnobiomedical field 
research at Shaman, “the word for 
diabetes means sweet urine.” 
The company has at least 15 
different compounds that lower 
blood glucose in an animal model, 
including triterpenoids, cryptolepine, 
and SP-134101, a compound now 
entering Phase I trials. 
Unfractionated plant extracts are first 
tested in a mouse deficient in the 
leptin receptor (d&#), and the most 
promising candidates advance to the 
more sophisticated rat model. The 
two treatments used to construct the 
rat model - a high lipid diet to build 
peripheral insulin resistance, 
followed by streptozocin, a drug that 
kills pancreatic cells - mimics the 
biphasic disease course in humans. 
From plant to pill 
Modern analytical methods, 
particularly two-dimensional nuclear 
magnetic resonance, have reduced 
the amount of raw material needed 
to determine the structure of a 
natural product. Synthetic chemistry 
then comes in as a source of material 
for biological trials, or even as the 
creator of modified drugs. “The 
original philosophy was that from the 
ethnobotanical source would come a 
compound that would go all the way 
to being a drug,” says Donald Bierer, 
associate director of medicinal 
chemistry at Shaman. “The reality is 
that this won’t always be the case.” 
Bierer has modified various natural 
products to reduce toxicity, increase 
efficacy, and even remove extraneous 
chemical complexity. “If it’s a 
complicated natural product that 
can’t be isolated in a large quantity 
without depleting the plant species 
in nature, then we need to simplify 
its structure,” he says. Bierer has not 
succeeded in simplifying or 
synthesizing Provir, but the 
abundance and fast growth of Croton 
lec/zleti and high yield of the 
compound (2%) mean that collection 
in the field is a viable option. 
No more raping and pillaging 
The Convention on Biological 
Diversity (CBD), arising from the Rio 
Earth Summit in 1992, included sharp 
admonitions that native people 
should be compensated for their 
medicinal knowledge. There are still 
few laws to make sure that this takes 
place, but Shaman has heavily 
promoted its own voluntary efforts to 
do so. “The countries and cultures are 
part of our R&D and they are pivotal 
in this process,” says Carlson. “That’s 
where it starts, with these people. 
They are and will be beneficiaries.” 
Eloy Rodriguez, an ethnobotanist 
at Cornell IJniversity (Ithaca, New 
York), admits he does not know the 
details of Shaman’s efforts. But he is 
cautious of their claims. “After all,” 
he says, “exploitation has been the 
history of the world.” And the 
realities of the world mean that only 
those in the developed world, with 
diseases of the developed world, have 
the money to buy drugs and bankroll 
further research. “Pharmaceutical 
companies are concerned about 
CEOs who are running around golf 
courses about to have heart attacks,” 
says Rodriguez. “The people in the 
rainforest are worried about malaria, 
dengue, [and] rotavirus.” 
Carlson admits that native peoples, 
even if they are interested in the 
diseases investigated by Shaman, will 
probably not be able to afford the final 
product. But that, he says, is not the 
point. “The whole notion that they 
would need a pure compound doesn’t 
make sense, because they already 
have the whole plant traditional 
medicine.” Shaman’s role, says 
Carlson, is to confirm the biological 
activity of certain plants (assay results 
are returned to the native 
collaborators), and to fund efforts to 
preserve and extend native 
knowledge of plant-based treatments 
used for other diseases such as malaria. 
A percentage (yet to be determined) 
of drug revenues will be given to the 
Healing Forest Conservancy (HFC), a 
non-profit set up by Shaman. The 
HFC will then distribute the money 
equally to ail government and 
community collaborators. A trial run, 
using a grant of $40,000 from the 
HFC, is underway in Nigeria. 
But that’s not all. “If the benefits 
they get are only on revenues, the 
time they have to wait is far too long,” 
says Carlson. Shaman therefore sets 
aside LO-15% of the budget of each 
expedition for short-term projects to 
be selected by the hosts: school desks 
and a hospital in Tanzania, an 
extended airstrip in Ecuador, legal 
expertise for land demarcation in 
Peru, and a clean-water project in 
Indonesia. Scientists from six 
countries have also visited and worked 
at Shaman, and Shaman has organized 
workshops on collecting and 
categorizing native plant knowledge. 
When and if the money starts to 
flow in greater amounts, the 
distribution politics will also intensify. 
“To do good well is not easy,” says 
Carlson. “But we believe that, with 
our long-term working relationships 
in tropical countries, we’re up to the 
challenge.” If all works as planned, 
Carlson will be part of a new way, a 
future with mutual cultural respect. 
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